Form 4: Intra-Cellular Therapies Executive Receives Stock Grant

Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., was granted 26,227 restricted stock units on March 1, 2024.

Summary

• Suresh K. Durgam, the EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., received a grant of 26,227 restricted stock units on March 1, 2024.
• These restricted stock units vest in three equal annual installments, starting on the first anniversary of the grant date.
• Each restricted stock unit represents the right to receive one share of Intra-Cellular Therapies common stock.

Sentiment

Score: 7

Explanation: The document indicates standard executive compensation practices, which is generally viewed neutrally to positively. It suggests alignment of management interests with shareholders.

Positives

• The grant of restricted stock units to a key executive aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The restricted stock units will vest over the next three years, incentivizing the executive to contribute to the company's long-term success.

Industry Context

Stock grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock grants and options as part of their compensation strategy to incentivize key personnel.
• The vesting schedule of three years is also fairly standard within the industry.

Stakeholder Impact

• Shareholders may view the stock grant positively as it aligns executive interests with company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates